Effect of 5-alpha Reductase Inhibitor on Storage Symptoms in Patients with Benign Prostatic Hyperplasia
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: Many patients with benign prostatic hyperplasia (BPH) have storage symptoms. The aim of this study was to evaluate the effects of treatment with a 5-alpha reductase inhibitor (5ARI) on storage symptoms in patients with BPH. Methods: This study was conducted in 738 patients with lower urinary tract symptoms secondary to BPH. Patients with a prostate volume of higher than 30 mL on the transrectal ultrasound were classified into two groups: group A, in which an alpha blocker was solely administered for at least 12 months, and group B, in which a combination treatment regimen of an alpha blocker plus 5ARI was used. This was followed by an analysis of the changes in parameters such as the total International Prostate Symptom Score (IPSS), voiding symptom subscore, and storage symptom subscore between the two groups. In addition, we examined whether there was a significant difference between the two groups in the degree of change in storage symptoms between before and after the pharmacological treatment. Results: Of the 738 men, 331 had a prostate volume ≥30 mL, including 150 patients in group A and 181 patients in group B. Total IPSS, the voiding symptom subscore, and the storage symptom subscore were significantly lower after treatment than before treatment in both groups (P<0.05). A comparison of the degree of change between before and after treatment, however, showed no significant differences in the storage symptom subscore between the two groups (P>0.05). Conclusions: Alpha blocker and 5ARI combination treatment is effective for patients with BPH including storage symptoms. However, 5ARI does not exert a significant effect on storage symptoms in BPH patients.
Abstract
Purpose: Many patients with benign prostatic hyperplasia (BPH) have storage symptoms. The aim of this study was to evaluate the effects of treatment with a 5-alpha reductase inhibitor (5ARI) on storage symptoms in patients with BPH. Methods: This study was conducted in 738 patients with lower urinary tract symptoms secondary to BPH. Patients with a prostate volume of higher than 30 mL on the transrectal ultrasound were classified into two groups: group A, in which an alpha blocker was solely administered for at least 12 months, and group B, in which a combination treatment regimen of an alpha blocker plus 5ARI was used. This was followed by an analysis of the changes in parameters such as the total International Prostate Symptom Score (IPSS), voiding symptom subscore, and storage symptom subscore between the two groups. In addition, we examined whether there was a significant difference between the two groups in the degree of change in storage symptoms between before and after the pharmacological treatment. Results: Of the 738 men, 331 had a prostate volume ≥30 mL, including 150 patients in group A and 181 patients in group B. Total IPSS, the voiding symptom subscore, and the storage symptom subscore were significantly lower after treatment than before treatment in both groups (P<0.05). A comparison of the degree of change between before and after treatment, however, showed no significant differences in the storage symptom subscore between the two groups (P>0.05). Conclusions: Alpha blocker and 5ARI combination treatment is effective for patients with BPH including storage symptoms. However, 5ARI does not exert a significant effect on storage symptoms in BPH patients.
참고문헌 (22)
- Chapple CR, "Pharmacological therapy of benign prostatic hyperplasia", lower urinary tract symptoms: an overview for the practising clinician, 2004, pp.94, 738~744
- McConnell JD, "The pathophysiology of benign prostatic hyperplasia", J Androl, 12, pp.356~363 (1991)
- Glassman DT, "Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia", Prostate, 46, pp.45~51 (2001)
- Irwin DE, "Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study", Eur Urol, 50, pp.1306~1314 (2006)
- Djavan B, "Lower urinary tract symptoms", benign prostatic hyperplasia: fast control of the patient’s quality of life, 2003, pp.62(3 Suppl 1), 6~14
- Roehrborn CG, "Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations", Rev Urol, 10, pp.14~25 (2008)
- Mirone V, "The detrusor muscle: an innocent victim of bladder outlet obstruction", Eur Urol, 51, pp.57~66 (2007)
- AUA Practice Guidelines Committee, "AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations", J Urol, 170(2 Pt 1), pp.530~547 (2003)
- Madersbacher S, "EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines)", Eur Urol, 46, pp.547~554 (2004)
- 오철용, "Korean Urologist’s View of Practice Patterns in Diagnosis and Management of Benign Prostatic Hyperplasia: A Nationwide Survey", Yonsei Medical Journal, 51(2), pp.248~252 (2010), 연세대학교의과대학
- Vesely S, "Relationship between age, prostate volume, prostate-specific antigen, symptom score and uroflowmetry in men with lower urinary tract symptoms", Scand J Urol Nephrol, 37, pp.322~328 (2003)
- Lepor H, "A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia", J Urol, 148, pp.1467~1474 (1992)
- Takahashi S, "Clinical efficacy of an alpha1A", D-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia, 2006, pp.13, 15~20
- Yamanishi T, "Urodynamic effects of silodosin, a new alpha 1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia", Neurourol Urodyn, 29, pp.558~562 (2010)
- Malloy BJ, "Alpha1-adrenergic receptor subtypes in human detrusor", J Urol, 160(3 Pt 1), pp.937~943 (1998)
- Yokoyama O, "Selective α1A-blocker improves bladder storage function in rats via suppression of C-fiber afferent activity", World J Urol, 28, pp.609~614 (2010)
- Becher E, "The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study", Prostate Cancer Prostatic Dis, 12, pp.369~374 (2009)
- Lee JY, "Change in International Prostate Symptom Storage Subscore After Long-term Medical Therapy in BPH Patients: Finasteride and Alpha-blocker Combination Therapy in Men With Moderate-to-severe LUTS", BPH in Korea, 201101, pp.77(1), 171~176[DOI]
- Debruyne F, "Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia", Eur Urol, 46, pp.488~494 (2004)
- 배재현, "Efficacy and Safety of Low-Dose Propiverine in Patients with Lower Urinary Tract Symptoms", Benign Prostatic Hyperplasia with Storage Symptoms: A Prospective, Randomized, Single-Blinded and Multicenter Clinical Trial, 2011, pp.52(4), 274~278[DOI]
- Yang Y, "Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study", Chin Med J, 120, pp.370~374 (2007)
- Montorsi F, "The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) study", BJU Int, 107, pp.1426~1431 (2011)